Data show ultrafiltration for post-operative CABG patients provides a safe and effective method for managing fluid balance and reducing mortality rates MINNEAPOLIS, Aug. 31, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people […]
Coronary/Structural Heart
Hello Heart Announces a Groundbreaking Feature for Managing Cholesterol, Becoming the First and Only Digital Therapeutic to Tackle Whole-Heart Health
As we approach National Cholesterol Education Month, My Cholesterol will provide millions of users with clarity on their cholesterol and triglycerides trends through personalized, gender-specific insights and coaching MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart […]
New Data Show Abbott’s HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who […]
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of <55 mg/dL at Week 12 Data Presented at ESC 2022 and Simultaneously Published in Circulation THOUSAND […]
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
— Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis — –– Data Presented as an Oral Abstract at European Society of […]
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of FARXIGA in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting […]
Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy
~30% relative risk reduction seen in symptomatic ischemic strokes in three milvexian arms compared to placebo; dose response not observed for primary study objective No fatal bleeding and no increase in symptomatic intracranial hemorrhage observed in patients treated with milvexian, […]
Large Atrial Thrombus Percutaneously Removed Using the ŌNŌ Retrieval System ŌNŌCOR Reports First-In-Human Use for Removal of an Atrial Blood Clot
PHILADELPHIA, Aug. 25, 2022 (GLOBE NEWSWIRE) — ŌNŌCOR LLC announced the use of the ŌNŌ endovascular retrieval system to remove a large central-line-associated thrombus from the right atrium in a teenage patient. The team at Children’s Hospital Los Angeles (CHLA, @ChildrensLA), led by Dr. Darren […]
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
— Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses — — Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congress 2022 in Barcelona — DUBLIN, Ireland […]
Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022
Treatment with ninerafaxstat significantly improved cardiac energetics, steatosis and left ventricular (LV) diastolic function in patients with type-2 diabetes mellitus (T2DM) and obesity BOSTON, Mass., Aug. 26, 2022 (GLOBE NEWSWIRE) — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing […]